Lv2
200 积分 2021-10-28 加入
Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3Kα with superior anticancer activity
5小时前
待确认
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
16天前
已完结
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
22天前
已完结
Characterizing the Cooperative Effect of PROTAC Systems with End-Point Binding Free Energy Calculation
29天前
已完结
EED Maintains the Small Cell Lung Cancer Neuroendocrine Phenotype and Drives Lung Cancer Histological Transformation
1个月前
已完结
Molecular glues that facilitate RAS binding to PI3Kα promote glucose uptake without insulin
2个月前
已完结
Targeted protein degradation: from mechanisms to clinic
2个月前
已完结
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus
2个月前
已完结
Identification of a Primary Target of Thalidomide Teratogenicity
2个月前
已完结
Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition
2个月前
已完结
皖公网安备34019202002308
